Inflammation Markers and Prediction of Post-stroke Vascular Disease Recurrence: the MITICO Study

Overview

Journal J Neurol

Specialty Neurology

Date 2009 Mar 3

PMID 19252763

Citations 34

Authors

J Castillo

J Alvarez-Sabin

E Martinez-Vila

J Montaner

T Sobrino

J Vivancos

Affiliations

Soon will be listed here.

Abstract

Objective: Vascular disease recurrence following stroke is the main cause of morbidity and mortality. The MITICO study was designed to assess the prognostic value of markers of inflammation in relation to the risk of recurrence of vascular disease.

Patients And Methods: Multi-centered prospective observational study, in patients with ischemic stroke not receiving anti-coagulation therapy and who were recruited within 1-3 months from stroke onset. Blood samples were obtained at baseline and follow- up for the determination of high-sensitive C reactive protein (CRP), IL-6, IL-10, ICAM-1, VCAM- 1, MMP-9 and cellular fibronectin. Four follow-up visits within the first year were to rule out recurrence.

Results: Of 965 patients from 65 hospitals, 780 (aged 67.5+/-11.2 years, 33.6 % female) were valid for main analysis. One-hundred and three patients (13.2 %) had a new adverse vascular event and 116 patients (14.9 %) a vascular event or vascular death (66.4 % stroke, 21.5 % coronary and 12.1 % peripheral). Levels of IL-6 > 5 pg/mL and VCAM-1 > 1350 ng/mL (ROC curve analyses) were associated with vascular disease recurrence risk (OR: 28.7; 95 % CI: 14.2-58.0 vs. OR: 4.1; 95 % CI: 2.4-7.1, respectively) following adjustment for confounding variables. Risk of adverse vascular event or death from vascular disease were associated with IL-6 (OR: 21.2; 95 % CI: 11.6-38.7) and VCAM-1 (OR: 3.8; 95 % CI: 2.3-6.4).

Conclusions: Baseline values of IL-6 > 5 pg/mL and VCAM-1 > 1350 ng/mL increase 21-fold and 4-fold, respectively, the risk of new vascular disease event or death from vascular disease in patients with ischemic stroke not receiving anti-coagulation treatment.

Citing Articles

IL-6 and stroke recurrence in ischemic stroke.

Jiang Y, Fan T Biomark Med. 2024; 18(17-18):739-747.

PMID: 39230474 PMC: 11457620. DOI: 10.1080/17520363.2024.2389038.

Nuciferine induces autophagy to relieve vascular cell adhesion molecule 1 activation via repressing the Akt/mTOR/AP1 signal pathway in the vascular endothelium.

Wei H, Yin Y, Yang W, Zhu J, Chen L, Guo R Front Pharmacol. 2023; 14:1264324.

PMID: 37841916 PMC: 10569124. DOI: 10.3389/fphar.2023.1264324.

Neuroinflammation and anti-inflammatory therapy for ischemic stroke.

Cao Y, Yue X, Jia M, Wang J Heliyon. 2023; 9(7):e17986.

PMID: 37519706 PMC: 10372247. DOI: 10.1016/j.heliyon.2023.e17986.

Role of plaque inflammation in symptomatic carotid stenosis.

Zheng Y, Lim M, Tan B, Chan B, Paliwal P, Jonathan O Front Neurol. 2023; 14:1086465.

PMID: 36761341 PMC: 9902904. DOI: 10.3389/fneur.2023.1086465.

Need for a Paradigm Shift in the Treatment of Ischemic Stroke: The Blood-Brain Barrier.

Alonso-Alonso M, Sampedro-Viana A, Fernandez-Rodicio S, Bazarra-Barreiros M, Ouro A, Sobrino T Int J Mol Sci. 2022; 23(16).

PMID: 36012745 PMC: 9409167. DOI: 10.3390/ijms23169486.

References

Castillo J, Moro M, Blanco M, Leira R, Serena J, Lizasoain I . The release of tumor necrosis factor-alpha is associated with ischemic tolerance in human stroke. Ann Neurol. 2003; 54(6):811-9. DOI: 10.1002/ana.10765. View

Yokota C, Minematsu K, Hasegawa Y, Yamaguchi T . Long-term prognosis, by stroke subtypes, after a first-ever stroke: a hospital-based study over a 20-year period. Cerebrovasc Dis. 2004; 18(2):111-6. DOI: 10.1159/000079258. View

Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein L, Hennerici M, Rudolph A . High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355(6):549-59. DOI: 10.1056/NEJMoa061894. View

Brown R, Whisnant J, Sicks J, OFallon W, Wiebers D . Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996; 27(3):373-80. View

Elneihoum A, Goransson M, Falke P, Janzon L . Three-year survival and recurrence after stroke in Malmö, Sweden: an analysis of stroke registry data. Stroke. 1998; 29(10):2114-7. DOI: 10.1161/01.str.29.10.2114. View

Sacco R, Foulkes M, Mohr J, Wolf P, Hier D, Price T . Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke. 1989; 20(8):983-9. DOI: 10.1161/01.str.20.8.983. View

Hankey G, Jamrozik K, Broadhurst R, Forbes S, Burvill P, Anderson C . Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke. 1998; 29(12):2491-500. DOI: 10.1161/01.str.29.12.2491. View

Hillen T, Coshall C, Tilling K, Rudd A, McGovern R, Wolfe C . Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003; 34(6):1457-63. DOI: 10.1161/01.STR.0000072985.24967.7F. View

Stegmayr B, Asplund K . Exploring the declining case fatality in acute stroke. Population-based observations in the northern Sweden MONICA Project. J Intern Med. 1996; 240(3):143-9. DOI: 10.1046/j.1365-2796.1996.519857000.x. View

10.

Ross G, Petrovitch H, White L, Masaki K, Li C, Curb J . Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology. 1999; 53(2):337-43. DOI: 10.1212/wnl.53.2.337. View

11.

Dhamoon M, Sciacca R, Rundek T, Sacco R, Elkind M . Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology. 2006; 66(5):641-6. DOI: 10.1212/01.wnl.0000201253.93811.f6. View

12.

Bonetti P, Lerman L, Lerman A . Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23(2):168-75. DOI: 10.1161/01.atv.0000051384.43104.fc. View

13.

Harris A, Hutchinson J, Sachidanandam K, Johnson M, Dorrance A, Stepp D . Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes. 2005; 54(9):2638-44. DOI: 10.2337/diabetes.54.9.2638. View

14.

Friday G, Alter M, Lai S . Control of hypertension and risk of stroke recurrence. Stroke. 2002; 33(11):2652-7. DOI: 10.1161/01.str.0000033929.62136.6f. View

15.

Dorrance A, Rupp N, Nogueira E . Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension. 2005; 47(3):590-5. DOI: 10.1161/01.HYP.0000196945.73586.0d. View

16.

Gilbert R, Rumble J, Cao Z, Cox A, van Eeden P, Allen T . Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res. 2000; 86(2):158-65. DOI: 10.1161/01.res.86.2.158. View

17.

Chamorro A, Hallenbeck J . The harms and benefits of inflammatory and immune responses in vascular disease. Stroke. 2006; 37(2):291-3. PMC: 1852506. DOI: 10.1161/01.STR.0000200561.69611.f8. View

18.

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

19.

. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348(9038):1329-39. DOI: 10.1016/s0140-6736(96)09457-3. View

20.

Castillo J, Leira R . Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms. Would its early treatment be useful?. Cerebrovasc Dis. 2001; 11 Suppl 1:40-8. DOI: 10.1159/000049124. View